BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) reported today that researchers at the Wayne State University School of Medicine and the Kresge Eye Institute in Detroit, Michigan, published an article in the medical journal, Clinical Ophthalmology (Online pre-publication) entitled, “Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.” The researchers reviewed the multiple mechanisms of action associated with the molecule and its role in maintaining a healthy, functional cornea.
